Table 1.
Mean summary scores for the patient groups and controls.
| Age | F/M | Age of onset | Years diagnosis | MMSEa | ACERb |
ACER subscales |
CBId | PSP rating | UPDRSe | Medication |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Attention | Memory | Fluency | Language | VSpc | SAf | DAg | |||||||||
| bvFTD | 60.2 | 8/9 | 56.1 | 3.8 | 23.2 | 67.8 | 14.5 | 15.4 | 3.6 | 21.6 | 12.8 | 104 | ~ | ~ | 6 | 3 |
| n = 17 | (6.9) | (8.2) | (2.1) | (4.2) | (14.1) | (2.9) | (6.8) | (2.9) | (4.1) | (2.9) | (50) | |||||
| PSP | 67.5 | 2/8 | 64 | 4.2 | 26.5 | 75.8 | 16.2 | 19.6 | 4.4 | 22.6 | 11.7 | 69.5 | 27.8 | 26.6 | 3 | 7 |
| n = 10 | (7.3) | (8.1) | (1.5) | (3.2) | (17.6) | (1.4) | (6.9) | (3.2) | (5.7) | (5) | (28.8) | (9.7) | (12.5) | |||
| Controls | 65.7 | 15/19 | ||||||||||||||
| n = 34 | (7.4) | |||||||||||||||
a
MMSE: 30-point mini mental state examination.
b
ACER: 100 point Addenbrooke's cognitive examination revised.
c
VSp visuospatial subscale.
d
CBI: Cambridge Behavioural Inventory (Wedderburn et al., 2008).
e
UPDRS: Unified Parkinson's Disease Rating Scale.
f
SA: Serotonin agonists/reuptake inhibitors, including citalopram, venlafaxine, and trazodone.
g
DA: Dopamine agonists/reuptake inhibitors, including Madopar, Sinemet and Amantadine. Standard deviation in parenthesis.